GB0402679D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0402679D0
GB0402679D0 GBGB0402679.5A GB0402679A GB0402679D0 GB 0402679 D0 GB0402679 D0 GB 0402679D0 GB 0402679 A GB0402679 A GB 0402679A GB 0402679 D0 GB0402679 D0 GB 0402679D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
arylcarbonylamino
ibs
pent
cough
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0402679.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0402679.5A priority Critical patent/GB0402679D0/en
Publication of GB0402679D0 publication Critical patent/GB0402679D0/en
Priority to CN2005800081031A priority patent/CN1929817B/en
Priority to RU2006131788/15A priority patent/RU2397759C2/en
Priority to BRPI0507492-4A priority patent/BRPI0507492A/en
Priority to AU2005210134A priority patent/AU2005210134B2/en
Priority to PCT/EP2005/001166 priority patent/WO2005074891A1/en
Priority to CA002553658A priority patent/CA2553658A1/en
Priority to PT05707213T priority patent/PT1715848E/en
Priority to ES05707213T priority patent/ES2349647T3/en
Priority to AT05707213T priority patent/ATE475409T1/en
Priority to EP05707213A priority patent/EP1715848B1/en
Priority to US10/597,313 priority patent/US20080254113A1/en
Priority to DE602005022558T priority patent/DE602005022558D1/en
Priority to PL05707213T priority patent/PL1715848T3/en
Priority to JP2006551813A priority patent/JP2007520521A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to dispersible pharmaceutical compositions in which the active agent is a substance P antagonist, in particular a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide, that is useful for the treatment and prevention of respiratory diseases including asthma and chronic obstructive pulmonary disease, bowel disorders including irritable bowel syndrome (IBS), urinary incontinence, and cough.
GBGB0402679.5A 2004-02-06 2004-02-06 Organic compounds Ceased GB0402679D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB0402679.5A GB0402679D0 (en) 2004-02-06 2004-02-06 Organic compounds
JP2006551813A JP2007520521A (en) 2004-02-06 2005-02-04 Microemulsion formulation comprising a specific substance P antagonist
CA002553658A CA2553658A1 (en) 2004-02-06 2005-02-04 Microemulsion formulations comprising particular substance p antagonists
ES05707213T ES2349647T3 (en) 2004-02-06 2005-02-04 MICROEMULSION FORMULATIONS THAT INCLUDE PARTICULAR SUBSTANCE ANTAGONISTS.
BRPI0507492-4A BRPI0507492A (en) 2004-02-06 2005-02-04 microemulsion formulations comprising p-substance antagonists
AU2005210134A AU2005210134B2 (en) 2004-02-06 2005-02-04 Microemulsion formulations comprising particular substance P antagonists
PCT/EP2005/001166 WO2005074891A1 (en) 2004-02-06 2005-02-04 Microemulsion formulations comprising particular substance p antagonists
CN2005800081031A CN1929817B (en) 2004-02-06 2005-02-04 Microemulsion formulations comprising particular substance P antagonists
PT05707213T PT1715848E (en) 2004-02-06 2005-02-04 Microemulsion formulations comprising particular substance p antagonists
RU2006131788/15A RU2397759C2 (en) 2004-02-06 2005-02-04 Microemulsion compositions including substance p antagonists
AT05707213T ATE475409T1 (en) 2004-02-06 2005-02-04 MICROEMULSION FORMULATIONS WITH CERTAIN SUBSTANCE PANTAGONISTS
EP05707213A EP1715848B1 (en) 2004-02-06 2005-02-04 Microemulsion formulations comprising particular substance p antagonists
US10/597,313 US20080254113A1 (en) 2004-02-06 2005-02-04 Microemulsion Formulations Comprising Particular Substance P Antagonists
DE602005022558T DE602005022558D1 (en) 2004-02-06 2005-02-04 MICROEMULSION FORMULATIONS WITH SPECIFIC SUBSTANCE P ANTAGONISTS
PL05707213T PL1715848T3 (en) 2004-02-06 2005-02-04 Microemulsion formulations comprising particular substance p antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0402679.5A GB0402679D0 (en) 2004-02-06 2004-02-06 Organic compounds

Publications (1)

Publication Number Publication Date
GB0402679D0 true GB0402679D0 (en) 2004-03-10

Family

ID=31985813

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0402679.5A Ceased GB0402679D0 (en) 2004-02-06 2004-02-06 Organic compounds

Country Status (15)

Country Link
US (1) US20080254113A1 (en)
EP (1) EP1715848B1 (en)
JP (1) JP2007520521A (en)
CN (1) CN1929817B (en)
AT (1) ATE475409T1 (en)
AU (1) AU2005210134B2 (en)
BR (1) BRPI0507492A (en)
CA (1) CA2553658A1 (en)
DE (1) DE602005022558D1 (en)
ES (1) ES2349647T3 (en)
GB (1) GB0402679D0 (en)
PL (1) PL1715848T3 (en)
PT (1) PT1715848E (en)
RU (1) RU2397759C2 (en)
WO (1) WO2005074891A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
RU2481822C1 (en) * 2012-02-21 2013-05-20 Автономная некоммерческая организация "Институт медико-биологических исследований и технологий" (АНО "ИМБИИТ") Microemulsive compositions for creation of transdermal and transmucosal forms of pharmaceutical medications and cosmetic preparations, and method of their application
RU2677346C2 (en) * 2013-01-14 2019-01-16 ИнФерст Хэлткэр Лимитед Compositions and methods for treating severe pain
JP2017500355A (en) * 2013-12-23 2017-01-05 ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッド Racecadotril composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132550A (en) * 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
DE69804624T2 (en) * 1997-07-29 2002-09-19 Upjohn Co SELF-TEMPERATURE FORMULATION CONTAINING LIPOPHILE COMPOUNDS
ATE238044T1 (en) * 1998-08-25 2003-05-15 Novartis Pharma Gmbh USE OF SUBSTANCE PANTAGONISTS TO TREAT CHRONIC FATIGUE SYNDROME AND/OR FIBROMYALGIA
SE0000774D0 (en) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
MY120392A (en) * 2000-06-08 2005-10-31 Hovid Berhad A novel drug delivery system : formulation for fat-soluble drugs

Also Published As

Publication number Publication date
JP2007520521A (en) 2007-07-26
PT1715848E (en) 2010-10-21
EP1715848B1 (en) 2010-07-28
BRPI0507492A (en) 2007-07-17
AU2005210134B2 (en) 2008-05-22
DE602005022558D1 (en) 2010-09-09
PL1715848T3 (en) 2011-01-31
ATE475409T1 (en) 2010-08-15
CA2553658A1 (en) 2005-08-18
EP1715848A1 (en) 2006-11-02
RU2397759C2 (en) 2010-08-27
RU2006131788A (en) 2008-03-20
US20080254113A1 (en) 2008-10-16
WO2005074891A1 (en) 2005-08-18
CN1929817A (en) 2007-03-14
ES2349647T3 (en) 2011-01-07
AU2005210134A1 (en) 2005-08-18
CN1929817B (en) 2012-04-25

Similar Documents

Publication Publication Date Title
MY151172A (en) Pyrimidine amide compounds as pgds inhibitors
WO2006121861A3 (en) Biphenylazetidinone cholesterol absorption inhibitors
MY154895A (en) Pyrimidine hydrazide compounds as pgds inhibitors
MX2009004289A (en) Tricyclic compounds as matrix metalloproteinase inhibitors.
BR0107934A (en) Pyrimidine Carboxamides Useful as Inhibitors of pde4 Isozymes
BRPI0610321B8 (en) imidazoquinolines as lipid kinase inhibitors, their use and preparation process, and pharmaceutical preparation
WO2007056219A3 (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
WO2008025787A3 (en) Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
UA112296C2 (en) DRY POWDER PREPARATION CONTAINING PHOSPHODIESTERASE INHIBITOR
EP1773374A4 (en) An agent comprising fgf2 as an effective ingredient for treatment or prevention of asthma and chronic obstructive pulmonary disease
EP1737499A4 (en) Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
TW200720236A (en) Organic compounds
IL193252A0 (en) N-hydroxyacrylamide compounds
IL185457A0 (en) 5-phenyl-pentanoic acid derivatives as metrix metalloproteinase inhibitors for the treatment of asthma and other diseases
UA87154C2 (en) Polysulfated glycosides and salts thereof
HRP20140707T1 (en) COMBINATION OF HMG-CoA REDUCTASE INHIBITORS ATORVASTATIN OR SIMVASTATIN WITH A PHOSPHODIESTERASE 4 INHIBITOR, SUCH AS ROFLUMILAST FOR THE TREATMENT OF INFLAMMATORY PULMONARY DISEASES
MY145919A (en) Pharmaceutical formulation comprising neurokinin antagonist
WO2008012338A3 (en) Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
MX2009008363A (en) Combination of a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist.
EA200601880A1 (en) SUBSTITUTED DERIVATIVES 4-ALKYL-AND 4-ALKANOILPIPERIDINE AND THEIR APPLICATION AS ANTAGONISTS OF NEUROKININS
EA200800183A1 (en) NEW INDOLKARBOXAMID DERIVATIVES CONTAINING THEIR PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT
PL1715848T3 (en) Microemulsion formulations comprising particular substance p antagonists
WO2005011594A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
UY30935A1 (en) COMBINATION: -ANTAGONIST OF THE CHEMIOQUINE RECEIVER 1 (CCR1) -AGONIST OF THE GLUCOCORTICOID RECEPTOR- OPTIONALLY AGONIST B (BETA) 2, - PHARMACEUTICAL COMPOSITION CONTAINING IT - APPLICATIONS.
MX2010004529A (en) Combination therapy.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)